<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04304651</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC20.0021</org_study_id>
    <nct_id>NCT04304651</nct_id>
  </id_info>
  <brief_title>Screening for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism</brief_title>
  <acronym>MVTEP2/SOME2</acronym>
  <official_title>Screening for Occult Malignancy Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in Patients With Unprovoked Venous Thromboembolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Venous thromboembolism (VTE) can be the earliest sign of cancer. Identifying occult cancers
      at the time of VTE diagnosis may lead to significant improvement of patients' care. This is
      also an upmost issue for patients who want to know if an underlying cancer might have
      triggered the VTE.

      An individual patient-level data meta-analysis (IPDMA) supports extensive screening
      strategies for occult cancer especially based on FDG PET/CT, and suggests that the best
      target population for cancer screening would be patients with unprovoked VTE older than 50
      years of age (6.7% in patients aged 50 years or more vs. 1.0% in patients of less than 50
      years (OR: 7.1, 95% CI: 3.1 to 16%).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The identification of subgroups of patients at high risk of cancer might enable more
      efficient screening strategies for early detection of cancer. Venous thromboembolism (VTE)
      can be the first manifestation of an occult cancer. All tumor sites may be involved. In an
      individual patient-level data meta-analysis (IPDMA), it was reported a 1-year prevalence of
      occult cancer of 5.2% (95%CI 4.1-6.5) among patients presenting with unprovoked VTE.

      Two recent multicenter randomized controlled trials (e.g. SOME (Canada) and MVTEP (France)
      trials) failed to demonstrate that extensive cancer screening strategies diagnosed more
      cancers, more early stage tumors, or improved cancer-related mortality in comparison with a
      more limited screening strategy. However, the main limitation of these studies was the twice
      lower than expected overall incidence of occult cancer diagnosis in unselected patients with
      unprovoked VTE, which limited the statistical power. In the IPDMA, it was also reported that
      the 1-year period prevalence of occult cancer was 7-fold higher in patients aged ≥ 50 (6.8%;
      95%CI 5.6-8.3) as compared with those &lt; 50 years (1.0%; 95%CI 0.5-2.3).

      Moreover, in the MVTEP trial, the incidence of missed cancers over a 2-years follow-up period
      was significantly lower in patients randomized to a 18F-Fluorodeoxyglucose Positron
      Emission/Computed Tomography (FDG-PET/CT) screening strategy. Thus, the most promising
      diagnostic modality for occult cancer screening seems to be FDG-PET/CT. FDG-PET/CT which
      allows a one-stop whole-body imaging, is routinely used for the diagnosis, staging and
      restaging of various cancers.

      The MVTEP2 Trial seeks to determine if among higher risk patients (≥ 50 year-old) with a
      first unprovoked VTE, a cancer screening strategy including a FDG-PET/CT decreases the number
      of missed occult cancers detected over a 1-year follow-up period as compared with a limited
      screening alone.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2, 2020</start_date>
  <completion_date type="Anticipated">September 2, 2028</completion_date>
  <primary_completion_date type="Anticipated">September 2, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occult cancer missed by screening strategies</measure>
    <time_frame>At 1 year of follow-up</time_frame>
    <description>Occult cancer &quot;missed&quot; by cancer screening defined as proven cancer diagnosed (either biopsy proven cancer or cancer diagnosis approved by adjudication committee in the absence of biopsy proven cancer) from the time of cancer screening completion to the end of the 1-year follow-up period, and not detected at the time of screening. In other words, &quot;missed&quot; means the number of new cancers diagnosed in patients considered not to have cancer after having completed the assigned cancer screening strategy (i.e false negative results of screening strategies).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occult cancer diagnosed by screening strategies</measure>
    <time_frame>At 1 month</time_frame>
    <description>The proportion of patients with a new cancer diagnosis after completion of the initial allocated screening strategy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early vs Adanced-stage cancers</measure>
    <time_frame>At 1 year of follow-up</time_frame>
    <description>The proportion of early-stage (T1-2N0M0) as per the World Health Organization TNM classification system) versus advanced-stage tumors at initial screening and during follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-related mortality</measure>
    <time_frame>At 5 years of follow-up</time_frame>
    <description>Cancer-related mortality during a 5-year follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness analysis</measure>
    <time_frame>At 1 year of follow-up</time_frame>
    <description>Additional cost per additional cancer detected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent VTE</measure>
    <time_frame>At 1 year of follow-up</time_frame>
    <description>Rate of recurrent VTE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decision aid to assist patients in the decision of cancer screening</measure>
    <time_frame>At 1 year of follow-up</time_frame>
    <description>Development of a decision aid to assist patients in the decision of cancer screening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional tests</measure>
    <time_frame>At 1 year of follow-up</time_frame>
    <description>The proportion of patients receiving additional tests following each strategy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1276</enrollment>
  <condition>Embolism and Thrombosis</condition>
  <arm_group>
    <arm_group_label>Limited cancer screening</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Limited screening alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Limited cancer screening + FDG PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Limited screening + FDG PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Limited cancer screening</intervention_name>
    <description>The limited cancer screening will include: 1) a complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin); and 4) chest X-ray.
In women, a breast examination, Pap smear/pelvic examination (if &lt; 70 years old and previously sexually active) and mammogram will be performed, if not conducted in last year.
In men, similarly, prostate examination and PSA testing will be performed, if not conducted in the last year.
All patients will undergo colon cancer screening as per local practice.</description>
    <arm_group_label>Limited cancer screening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Limited cancer screening + FDG PET/CT</intervention_name>
    <description>The limited cancer screening (as described above) in combination with a FDG PET/CT.</description>
    <arm_group_label>Limited cancer screening + FDG PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients aged 50 years or older with a new diagnosis of first unprovoked proximal deep vein
        thrombosis (DVT) and/or pulmonary embolism (PE) will be eligible to participate into the
        study.

        Unprovoked VTE is defined as the absence of any of the following predisposing factors:

          1. active malignancy (known malignancy, progressive and/or treated during the last 5
             years) except for adequately treated basal or squamous cell carcinoma;

          2. recent (less than 3 months) paralysis, paresis or plaster immobilization of the lower
             extremities;

          3. recently bedridden for period of 3 or more days, or major surgery, within the previous
             12 weeks requiring general or regional anaesthesia;

          4. previous unprovoked VTE;

          5. known thrombophilia (hereditary or acquired)

        Exclusion Criteria:

        Patients will be excluded from the study if they have any of the following criteria:

          1. Refusal or inability to provide informed consent;

          2. Hypersensitivity to 18F-FDG or any of the excipients according to the product
             monograph;

          3. Unavailable to follow-up.

          4. VTE while on anticoagulation (e.g apixaban, rivaroxaban, edoxaban, dabigatran,
             warfarin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre-Yves SALAUN</last_name>
    <phone>(+33)298223327</phone>
    <email>pierre-yves.salaun@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aurélien DELLUC</last_name>
    <email>adelluc@toh.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Leslie Skeith</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Ryan Zarychanski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Deborah Siegal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Alejandro Lazno-Langner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Montfort</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Gregoire Le Gal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Aurélien DELLUC</last_name>
      <email>adelluc@toh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Marc CARRIER</last_name>
      <email>mcarrier@toh.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Grégoire LE GAL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Phillippe Galanaud</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Erik Yeo</last_name>
    </contact>
    <contact_backup>
      <last_name>Jameel Abdulrehman</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Vicky Tagalakis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Susan Solymoss</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Agen</name>
      <address>
        <city>Agen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Albert TRINH-DUC</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre-Marie ROY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brest University Hospital</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre-Yves SALAUN</last_name>
      <email>pierre-yves.salaun@chu-brest.fr</email>
    </contact>
    <contact_backup>
      <last_name>Philippe ROBIN</last_name>
      <email>philippe.robin@chu-brest.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Francis COUTURAUD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Yves LE ROUX</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jeannot SCHMIDT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas FALVO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe LACROIX</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Guy MEYER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent BERTOLETTI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Dominique STEPHAN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Musse - CH Toulon</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Antoine ELIAS</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Robin P, Le Roux PY, Planquette B, Accassat S, Roy PM, Couturaud F, Ghazzar N, Prevot-Bitot N, Couturier O, Delluc A, Sanchez O, Tardy B, Le Gal G, Salaun PY; MVTEP study group. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncol. 2016 Feb;17(2):193-199. doi: 10.1016/S1470-2045(15)00480-5. Epub 2015 Dec 8.</citation>
    <PMID>26672686</PMID>
  </reference>
  <reference>
    <citation>Carrier M, Lazo-Langner A, Shivakumar S, Tagalakis V, Zarychanski R, Solymoss S, Routhier N, Douketis J, Danovitch K, Lee AY, Le Gal G, Wells PS, Corsi DJ, Ramsay T, Coyle D, Chagnon I, Kassam Z, Tao H, Rodger MA; SOME Investigators. Screening for Occult Cancer in Unprovoked Venous Thromboembolism. N Engl J Med. 2015 Aug 20;373(8):697-704. doi: 10.1056/NEJMoa1506623. Epub 2015 Jun 22.</citation>
    <PMID>26095467</PMID>
  </reference>
  <reference>
    <citation>van Es N, Le Gal G, Otten HM, Robin P, Piccioli A, Lecumberri R, Jara-Palomares L, Religa P, Rieu V, Rondina M, Beckers MM, Prandoni P, Salaun PY, Di Nisio M, Bossuyt PM, Büller HR, Carrier M. Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis of Individual Patient Data. Ann Intern Med. 2017 Sep 19;167(6):410-417. doi: 10.7326/M17-0868. Epub 2017 Aug 22. Review.</citation>
    <PMID>28828492</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 7, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>venous thrombosis</keyword>
  <keyword>pulmonary embolism</keyword>
  <keyword>screening</keyword>
  <keyword>occult cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Embolism and Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning three years and ending fifteen years following the final study report completion</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

